Latox (Nitrous Oxide, Oxygen)

Nitrous oxide works by blocking NMDA receptors, which reduces excitatory signaling in the central nervous system. It also enhances opioid receptor activity and potentiates GABA‑mediated inhibition, together producing analgesia, mild dissociation and a sedative state while generally preserving respiratory drive.

The specific concentration and duration of nitrous oxide administration are determined by the prescribing clinician based on the procedure, patient characteristics and monitoring requirements. Dosing is individualized and should follow institutional protocols and the prescriber’s orders.

Safety data for nitrous oxide in pregnancy and lactation are limited. It is classified as a Category C/unknown agent, so it should be used only when the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To request Latox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and import documentation.

Latox (nitrous oxide) offers rapid onset and quick recovery, making it suitable for short procedures and conscious sedation. Compared with volatile agents such as sevoflurane, nitrous oxide provides less profound anesthesia but has a lower risk of airway irritation and does not require a vaporizer, though it must be combined with oxygen to avoid hypoxia.

Latox is supplied in gas cylinders. Store them at ambient temperature, upright, away from direct sunlight, heat sources and moisture. Ensure cylinders are secured to prevent tipping, and follow local regulations for compressed gas handling and disposal.

Latox is delivered via a calibrated inhalation system that mixes nitrous oxide with oxygen, typically using a demand valve or a closed‑circuit delivery device. The clinician adjusts the nitrous oxide concentration while continuously monitoring the patient’s vital signs and oxygen saturation throughout the procedure.

The most serious risks include hypoxia if nitrous oxide is administered without adequate oxygen supplementation, respiratory depression in susceptible individuals, and rare events such as loss of consciousness or severe hypotension. Continuous monitoring and appropriate oxygen delivery are essential to mitigate these hazards.

Latox should be avoided in patients with severe chronic obstructive pulmonary disease, uncontrolled respiratory infections, known hypersensitivity to nitrous oxide, or those who cannot tolerate inhaled gases. Caution is also advised for individuals with vitamin B12 deficiency, pregnant women and patients receiving certain chemotherapeutic agents.